Live oral vaccines against cholera: an update - PubMed

Review

Live oral vaccines against cholera: an update

M M Levine et al. Vaccine. 1993.

Abstract

One hundred years elapsed between the first (live, parenteral) cholera vaccine that entered clinical trials in 1885 and the field trials of two oral inactivated cholera vaccines undertaken in Bangladesh in the mid-1980s. The oral inactivated vaccines advanced the art by establishing, convincingly, that oral vaccines could protect (although multiple doses were required) and that (at least in adults) protection could last 3 years. Attenuated Vibrio cholerae O1 strain CVD 103-HgR (deleted of the cholera toxin A subunit gene and harbouring a gene encoding resistance to Hg++) constitutes another significant advance. This live oral vaccine is well tolerated and highly immunogenic in adults and children and highly protective (in adult volunteer challenge studies) following ingestion of of a single dose.

Similar articles

• A review of the current status of enteric vaccines.

  Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.

• Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

  Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S. Levine MM, et al. Lancet. 1988 Aug 27;2(8609):467-70. doi: 10.1016/s0140-6736(88)90120-1. Lancet. 1988. PMID: 2900401 Clinical Trial.

• PaxVax CVD 103-HgR single-dose live oral cholera vaccine.

  Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.

• Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.

  Chowdhury MI, Sheikh A, Qadri F. Chowdhury MI, et al. Expert Rev Vaccines. 2009 Dec;8(12):1643-52. doi: 10.1586/erv.09.137. Expert Rev Vaccines. 2009. PMID: 19943759 Review.

• Cholera vaccines.

  Ryan ET, Calderwood SB. Ryan ET, et al. Clin Infect Dis. 2000 Aug;31(2):561-5. doi: 10.1086/313951. Epub 2000 Sep 7. Clin Infect Dis. 2000. PMID: 10987721 Review.

Cited by

• Helminth-Tuberculosis Co-infection: An Immunologic Perspective.

  Babu S, Nutman TB. Babu S, et al. Trends Immunol. 2016 Sep;37(9):597-607. doi: 10.1016/j.it.2016.07.005. Epub 2016 Aug 5. Trends Immunol. 2016. PMID: 27501916 Free PMC article. Review.

• Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

  Levine MM. Levine MM. BMC Biol. 2010 Oct 4;8:129. doi: 10.1186/1741-7007-8-129. BMC Biol. 2010. PMID: 20920375 Free PMC article. Review.

• Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

  Cryz SJ Jr, Que JU, Levine MM, Wiedermann G, Kollaritsch H. Cryz SJ Jr, et al. Infect Immun. 1995 Apr;63(4):1336-9. doi: 10.1128/iai.63.4.1336-1339.1995. Infect Immun. 1995. PMID: 7890391 Free PMC article. Clinical Trial.

• Validation of a volunteer model of cholera with frozen bacteria as the challenge.

  Sack DA, Tacket CO, Cohen MB, Sack RB, Losonsky GA, Shimko J, Nataro JP, Edelman R, Levine MM, Giannella RA, Schiff G, Lang D. Sack DA, et al. Infect Immun. 1998 May;66(5):1968-72. doi: 10.1128/IAI.66.5.1968-1972.1998. Infect Immun. 1998. PMID: 9573077 Free PMC article.

• Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

  Kollaritsch H, Furer E, Herzog C, Wiedermann G, Que JU, Cryz SJ Jr. Kollaritsch H, et al. Infect Immun. 1996 Apr;64(4):1454-7. doi: 10.1128/iai.64.4.1454-1457.1996. Infect Immun. 1996. PMID: 8606118 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database